

Caregiver Perspective of Benefits and Side Effects of Anti-seizure Medications in CDKL5 Deficiency Disorder from an International Database

Journal

CNS Drugs

Authors

Kingsley Wong¹, Mohammed Junaid¹, Solomon Alexander¹, Heather E. Olson², Elia M. Pestana-Knight³, Rajsekar R. Rajaraman⁴, Jenny Downs¹, Helen Leonard¹

Affiliations

1. Telethon Kids Institute, Centre for Child Health Research, The University of Western Australia, Perth, WA, Australia.
2. Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Department of Neurology, Boston Children's Hospital, Boston, MA, USA.
3. Cleveland Clinic, Neurological Institute, Cleveland, OH, USA.
4. UCLA Mattel Children's Hospital, Los Angeles, CA, USA.

Corresponding Author

A/Prof. Helen Leonard

Email: Helen.Leonard@telethonkids.org.au

Supplementary Table 1. Likelihood of any seizure-related benefits and worsening and any side effects associated with the use of antiseizure medications in 399 individuals with CDD

Antiseizure medication	n	Any benefits	Any worsening	Any side effects
		%, number of events/n		
Cannabidiol	70	80, 45/56	4, 2/56	13, 9/68
Carbamazepine	84	22, 9/41	5, 2/41	24, 17/72
Clobazam	219	46, 72/156	3, 5/156	50, 102/205
Clonazepam	132	48, 43/89	3, 3/89	38, 47/123
Clorazepate	13	50, 4/8	13, 1/8	17, 2/12
Ethosuximide	22	13, 1/8	0, 0/8	28, 5/18
Felbamate	31	40, 8/20	5, 1/20	33, 10/30
Gabapentin	17	40, 4/10	0, 0/10	6, 1/16
Steroids/ACTH	135	49, 42/86	5, 4/86	65, 84/129
Lacosamide	49	48, 16/33	3, 1/33	35, 16/46
Lamotrigine	135	52, 46/89	7, 6/89	24, 29/122
Levetiracetam	347	39, 90/231	2, 5/231	32, 102/321
Nitrazepam	21	44, 4/9	0, 0/9	28, 5/18
Oxcarbazepine	96	34, 20/59	8, 5/59	20, 18/88
Perampanel	31	62, 16/26	4, 1/26	42, 11/26
Phenobarbital	213	34, 43/127	2, 2/127	52, 103/199
Phenytoin	42	32, 8/25	4, 1/25	37, 13/35
Rufinamide	69	37, 19/52	6, 3/52	34, 21/62
Sulthiame	10	-	-	10, 1/10
Topiramate	264	49, 77/158	6, 9/158	38, 94/249
Sodium valproate	291	53, 102/194	1, 2/194	31, 82/266
Vigabatrin	243	56, 95/170	2, 4/170	37, 81/220
Zonisamide	105	48, 35/73	5, 4/73	31, 31/99

n, number of uses; ACTH, adrenocorticotrophic hormone

Supplementary Table 2. Encoded family provided comments on seizure-related benefits and worsening and medication side effects associated with the use of Cannabidiol and Perampanel

	Number of events
Cannabidiol	
Benefits	
Cognitive improvements	1
Decreased seizure frequency	8
Decreased seizure frequency and severity	3
Decreased seizure severity	4
Decreased seizure severity and spasms	1
General improvement in seizure control	2
Immediate reduction in seizures	1
Improved control of tonic-clonic seizures	1
Improved sleep	1
Major improvement in seizure control	3
More sociable	1
Overall improvement	1
Reduced seizure duration	1
Worsening	
Worsening of seizure	1
More frequency seizure	1
Side effects	
Increased appetite and bowel motions	1
Drowsiness and fatigue	1
Sleepiness and fatigue	5
Vomiting	1
Vomiting and nausea	1
Perampanel	
Benefits	
Decreased seizure frequency	2
Decreased seizure severity	4
General improvement in seizure control	1
Side effects	
Initial drowsiness, fatigue and over-excited	1
Initial fatigue	1
Initial irritability	1
Screaming	1
Sleepiness and fatigue	6
Vomiting	1

Supplementary Table 3. Frequency distribution of antiseizure medications currently used^a, by concurrent usage status, in 379 individuals with CDD

	Polytherapy	Monotherapy
<i>n</i>	1,111	95
Antiseizure medication	<i>n</i> (%)	
Sodium valproate	152 (13.7)	16 (16.8)
Levetiracetam	144 (13.0)	12 (12.6)
Clobazam	130 (11.7)	7 (7.4)
Vigabatrin	124 (11.2)	8 (8.4)
Topiramate	108 (9.7)	14 (14.7)
Lamotrigine	65 (5.9)	9 (9.5)
Clonazepam	58 (5.2)	1 (1.1)
Cannabidiol	57 (5.1)	4 (4.2)
Zonisamide	49 (4.4)	2 (2.1)
Phenobarbital	47 (4.2)	4 (4.2)
Rufinamide	32 (2.9)	4 (4.2)
Lacosamide	25 (2.3)	2 (2.1)
Oxcarbazepine	23 (2.1)	2 (2.1)
Perampanel	21 (1.9)	2 (2.1)
Carbamazepine	18 (1.6)	3 (3.2)
Corticosteroids/ACTH	13 (1.2)	0 (0)
Felbamate	12 (1.1)	2 (2.1)
Nitrazepam	10 (0.9)	0 (0)
Clorazepate	9 (0.8)	1 (1.1)
Gabapentin	5 (0.5)	1 (1.1)
Ethosuximide	4 (0.4)	0 (0)
Phenytoin	4 (0.4)	1 (1.1)
Sulthiame	1 (0.1)	0 (0)

^a currently used at the time of the baseline and/or the follow-up questionnaire
n, number of uses; ACTH, adrenocorticotrophic hormone

Supplementary Table 4. Likelihood of any seizure-related benefits and any side effects associated with selected^a concurrent antiseizure medications currently used^b in 379 individuals with CDD

ASM combination			n	Any benefits %, number of events/n	Any side effects n	Seizure frequency ^c			
1 st	2 nd	3 rd				Sz Free	Mild	Moderate	Severe
						n (%)			
LEV	TPM		13	75, 6/8	13	1 (8)	5 (38)	6 (46)	1 (8)
LEV	VGB		13	78, 7/9	10	0 (0)	2 (20)	4 (40)	4 (40)
VPA	CLB		13	63, 5/8	12	0 (0)	3 (25)	2 (17)	7 (58)
VPA	VGB		11	75, 6/8	10	0 (0)	3 (30)	4 (40)	3 (30)
VPA	LTG		7	83, 5/6	6	0 (0)	2 (33)	3 (50)	1 (17)
LEV	ZNS		7	100, 6/6	7	0 (0)	3 (43)	3 (43)	1 (14)
VGB	TPM		7	100, 4/4	7	0 (0)	1 (14)	5 (71)	1 (14)
VPA	LEV		6	100, 5/5	6	1 (17)	1 (17)	4 (67)	0 (0)
VPA	TPM		6	67, 2/3	5	0 (0)	2 (40)	3 (60)	0 (0)
VGB	ZNS		6	67, 4/6	5	0 (0)	2 (40)	2 (40)	1 (20)
CLB	TPM		6	80, 4/5	6	0 (0)	1 (17)	5 (83)	0 (0)
CLB	ZNS		5	100, 5/5	5	0 (0)	0 (0)	3 (60)	2 (40)
VPA	CLN		5	33, 1/3	5	1 (20)	2 (40)	1 (20)	1 (20)
LEV	OXC		4	66, 2/3	4	0 (0)	3 (75)	1 (25)	0 (0)
LEV	CLB		4	100, 1/1	4	1 (25)	2 (50)	0 (0)	1 (25)
VGB	CLN		4	100, 2/2	4	0 (0)	1 (25)	1 (25)	2 (50)
LEV	VPA	VGB	6	75, 3/4	4	0 (0)	0 (0)	2 (50)	2 (50)
LEV	VPA	CLB	6	100, 4/4	4	0 (0)	2 (33)	2 (33)	2 (33)

^a limited to dual or triple therapy used by at least 4 uses; ^b currently used at the time of the baseline and/or the follow-up questionnaire; ^c seizure frequency: Sz Free, seizure-free for at least 2 months; mild, weekly or less; moderate, 1-4 per day; severe, at least 5 per day
n, number of uses; ASM, antiseizure medication; LEV, levetiracetam; TPM, topiramate; VGB, vigabatrin; VPA, sodium valproate; CLB, clobazam; LTG, lamotrigine; ZNS, zonisamide; OXC, oxcarbazepine; CLN, clonazepam